pki

High affinity PKA inhibitor (Ki = 2.3 nM).

Donitriptan 是一种 5-HT 受体激动剂，对 5-HT1B 和 5-HT1D 的 pKi 分别为 9.4 和 9.3。

Pipamperone (McN-JR 3345) 是5-HT2A 受体和D4受体的高亲和力拮抗剂，也是D2受体的低亲和力拮抗剂，pKi 分别为 8.2、8.0 和 6.7。

Seltorexant hydrochloride is a selective, orally active and high-affinity antagonist of OX2R with pKi values of 8.0 and 8.1 for human and rat OX2R.

PKI-166是一种可口服的EGF-R 酪氨酸激酶抑制剂（IC50 ： 0.7 nM），具有有效性和选择性。PKI-166能有效抑制包括胰腺癌在内的多种人类癌细胞的生长和转移。

PKI-402 是一种有效的 PI3K 和 mTOR 抑制剂，对 PI3Kα, mTOR, PI3Kβ, PI3Kδ 和 PI3Kγ 抑制的IC50 分别为 2, 3, 7, 14 和 16 nM。

PKI (5-24) Acetate(99534-03-9 free base) 是一种高亲和力 PKA 抑制剂 (Ki = 2.3 nM)。

PKI 14-22 amide, myristoylated Acetate 抑制 cAMP 依赖性蛋白激酶 (PKA) 并阻断脊髓给药 8-溴-cAMP 产生的痛觉过敏。

PKI-179 is a potent and orally active dual PI3K mTOR inhibitor, with IC50s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 also exhibits activity over E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo[1][2]. PKI-179 inhibits the cell proliferation, with IC50s of 22 nM and 29 nM for MDA361 and PC3 cells, respectively[1].PKI-179 shows inhibitory activity against a panel of 361 other kinases, hERG and cytochrome P450 (CYP) isoforms at concentrations up to >30 μM, but does have activity for CYP2C8 (IC50=3 μM)[1]. PKI-179 (5-50 mg kg; p.o. once daily for 40 days) inhibits the tumor growth and is well tolerated in nude mice bearing MDA-361 human breast cancer tumors[1].PKI-179 (50 mg kg; p.o.) results in good inhibition of PI3K signaling in nude mice bearing MDA361 tumor xenografts[1].PKI-179 exhibits good oral bioavailability (98% in nude mouse, 46% in rat, 38% in monkey, and 61% in dog) and a high half-life (>60 min) [1]. [1]. Venkatesan AM, et, al. PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K) mammalian target of rapamycin (mTOR) inhibitor. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5869-73.[2]. Rehan M. A structural insight into the inhibitory mechanism of an orally active PI3K mTOR dual inhibitor, PKI-179 using computational approaches. J Mol Graph Model. 2015 Nov;62:226-234.

PKI-179 is an orally bioavailable dual inhibitor of PI3K and mammalian target of rapamycin (mTOR). In an in vitro enzymatic assay, it potently inhibits PI3K (IC50s = 8, 24, 17, and 74 nM for isoforms α, β, δ, and γ, respectively), two common PI3Kα mutants, E545K and H1047R (IC50s = 14 and 11 nM, respectively), and mTOR (IC50 = 0.42 nM). PKI-179 is selective for PI3K and mTOR over a panel of 361 other kinases at IC50 values up to 50 μM, hERG (IC50 > 30 μM), and cytochrome P450 (CYP) isoforms (IC50s > 30 μM), but does have activity for CYP2C8 (IC50 = 3 μM). It inhibits proliferation through the Akt/mTOR signaling pathway in MDA-361 breast and PC3MM2 prostate cancer cell lines in vitro (IC50s = 22 and 29 nM, respectively) and inhibits tumor growth in an MDA-361 mouse xenograft model when used at a dose of 50 mg/kg.

PKI(5-24) TFA 是一种强效、竞争性、合成的PKA(cAMP 依赖性蛋白激酶) 抑制剂，Ki 为 2.3 nM。PKI(5-24) TFA 对应于天然存在的热稳定蛋白激酶抑制剂中的 5-24 残基。

PKI 14-22 amide,myristoylated TFA 是一种有效的 cAMP 依赖性PKA 抑制剂。PKI 14-22 amide,myristoylated TFA 可降低IgG 介导的吞噬反应，也可抑制中性粒细胞粘附。

PKI(5-22)amide 是环 AMP 依赖性蛋白激酶 (PKA) 抑制剂的活性片段。PKI(5-22)amide 抑制PKA 激活，但不能减弱 CRF1 受体的同源脱敏作用。

PKI (14-24)amide 是一种有效的 PKA 抑制剂。PKI (14-24)amide 在细胞匀浆中强烈抑制环 AMP 依赖性蛋白激酶活性。

PKI (14-24)amide TFA 是一种有效的PKA 抑制剂。PKI (14-24)amide 在细胞匀浆中强烈抑制环 AMP 依赖性蛋白激酶活性。

PKI (5-24),amide (IP20-amide)为对应于cAMP依赖性蛋白激酶热稳定抑制蛋白活性部分的20残基肽。该化合物是一种高效的cAMP依赖性蛋白激酶(PKA)抑制剂，具有2.3 nM的Ki值。

Potent EGFR-kinase inhibitor (IC50 = 0.7 nM). Displays >3000-fold selectivity against a panel of serine/threonine kinases. Reduces metastasis and angiogenesis in a mouse model of pancreatic cancer. Antihypertensive and orally bioavailable. Bruns et al (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60 2926 PMID:10850439 |Ulu et al (2013) Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats. J.Pharmacol.Exp.Ther. 345 393 PMID:23528611 |Kaspersen et al (2012) Activity of 6-aryl-pyrrolo[2,3-d]pyrimidine-4-amines to Tetrahymena. Bioorg.Chem. 44 35 PMID:22832269

Gedatolisib (PF-05212384) 是一种高效的双重 PI3Kα (IC50:0.4 nM)，PI3Kγ (IC50:5.4 nM) 和 mTOR (IC50:1.6 nM)抑制剂。它在 mTOR 复合物mTORC1和mTORC2中同样有效。

Ampkinone is an indirect AMPK activator.

SRPKIN-1 is a covalent and irreversible inhibitor of SRPK1 2 (IC50s: 35.6 and 98 nM, respectively).

PKItide 的 IC50 值针对 cAMP-PK 为 0.2 μM。

Necrostatin-1 (Nec-1) 是一种坏死性凋亡抑制剂和 RIP1 抑制剂，具有特异性。Necrostatin-1 抑制 TNF-α 诱导的坏死性凋亡。Necrostatin-1 也可以抑制 IDO。

Staurosporine (AM-2282) 是一种蛋白激酶抑制剂，对 PKC、PKA、c-Fgr、Phosphorylase kinase 和 TAOK2 均有抑制活性 (IC50=6 15 2 3 3000 nM)，具有 ATP 竞争性和非选择性。Staurosporine 也可以诱导凋亡。

CMF019 是一种有效的小分子 Apelin receptor (APJ) 激动剂，具有 G protein 偏向性。 CMF019 在人，大鼠和小鼠中与 APJ 结合的 pKi 值分别为 8.58、8.49 和 8.71。CMF-019 在啮齿动物中的有益于心血管。 Apelin 受体 (APJ) 是由内源性肽 apelin 激活的 G 蛋白偶联受体(GPCR)。